Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 14 entries
Sorted by: Best Match Show Resources per page
Mechanisms of resistance to piperacillin of Enterobacter cloacae strains differ by antibiotic prescription policy.

International journal of antimicrobial agents

Namavar F, Verboom T, van de Klundert JA, van Gestel MH, Zaal J, Maclarena DM.
PMID: 18611803
Int J Antimicrob Agents. 1997;8(3):205-8. doi: 10.1016/s0924-8579(97)00377-4.

During a study of piperacillin resistance among aerobic Gram-negative bacteria, 18 resistant strains of Enterobacter cloacae were obtained from a General Hospital in Rotterdam and 13 from a University Hospital in Amsterdam. The patterns of antibiotic susceptibilities were different:...

Cite
Namavar F, Verboom T, van de Klundert JA, et al. Mechanisms of resistance to piperacillin of Enterobacter cloacae strains differ by antibiotic prescription policy. Int J Antimicrob Agents. 1997;8(3):205-8doi: 10.1016/s0924-8579(97)00377-4.
Namavar, F., Verboom, T., van de Klundert, J. A., van Gestel, M. H., Zaal, J., & Maclarena, D. M. (1997). Mechanisms of resistance to piperacillin of Enterobacter cloacae strains differ by antibiotic prescription policy. International journal of antimicrobial agents, 8(3), 205-8. https://doi.org/10.1016/s0924-8579(97)00377-4
Namavar, F, et al. "Mechanisms of resistance to piperacillin of Enterobacter cloacae strains differ by antibiotic prescription policy." International journal of antimicrobial agents vol. 8,3 (1997): 205-8. doi: https://doi.org/10.1016/s0924-8579(97)00377-4
Namavar F, Verboom T, van de Klundert JA, van Gestel MH, Zaal J, Maclarena DM. Mechanisms of resistance to piperacillin of Enterobacter cloacae strains differ by antibiotic prescription policy. Int J Antimicrob Agents. 1997;8(3):205-8. doi: 10.1016/s0924-8579(97)00377-4. PMID: 18611803.
Copy Download .nbib Format: NLM
In vitro activities of two drug combinations of ceftazidime, cefotaxime, cefuroxime, ciprofloxacin, chloramphenicol, imipenem and temocillin against clinical isolates of Pseudomonas cepacia from patients with cystic fibrosis.

International journal of antimicrobial agents

Kerr JR.
PMID: 18611561
Int J Antimicrob Agents. 1993;3(3):205-9. doi: 10.1016/0924-8579(93)90013-u.

This study utilised the killing curve method to determine the in vitro effects of all possible two drug combinations of ceftazidine, cefotaxime, cefuroxime, ciprofloxacin, chloramphenicol, imipenem and temocillin against 10 strains of Pseudomonas cepacia isolated from the sputa of...

Cite
Kerr JR. In vitro activities of two drug combinations of ceftazidime, cefotaxime, cefuroxime, ciprofloxacin, chloramphenicol, imipenem and temocillin against clinical isolates of Pseudomonas cepacia from patients with cystic fibrosis. Int J Antimicrob Agents. 1993;3(3):205-9doi: 10.1016/0924-8579(93)90013-u.
Kerr, J. R. (1993). In vitro activities of two drug combinations of ceftazidime, cefotaxime, cefuroxime, ciprofloxacin, chloramphenicol, imipenem and temocillin against clinical isolates of Pseudomonas cepacia from patients with cystic fibrosis. International journal of antimicrobial agents, 3(3), 205-9. https://doi.org/10.1016/0924-8579(93)90013-u
Kerr, J R. "In vitro activities of two drug combinations of ceftazidime, cefotaxime, cefuroxime, ciprofloxacin, chloramphenicol, imipenem and temocillin against clinical isolates of Pseudomonas cepacia from patients with cystic fibrosis." International journal of antimicrobial agents vol. 3,3 (1993): 205-9. doi: https://doi.org/10.1016/0924-8579(93)90013-u
Kerr JR. In vitro activities of two drug combinations of ceftazidime, cefotaxime, cefuroxime, ciprofloxacin, chloramphenicol, imipenem and temocillin against clinical isolates of Pseudomonas cepacia from patients with cystic fibrosis. Int J Antimicrob Agents. 1993;3(3):205-9. doi: 10.1016/0924-8579(93)90013-u. PMID: 18611561.
Copy Download .nbib Format: NLM
An Update on Eight "New" Antibiotics against Multidrug-Resistant Gram-Negative Bacteria.

Journal of clinical medicine

Yusuf E, Bax HI, Verkaik NJ, van Westreenen M.
PMID: 33806604
J Clin Med. 2021 Mar 04;10(5). doi: 10.3390/jcm10051068.

Infections in the ICU are often caused by Gram-negative bacteria. When these microorganisms are resistant to third-generation cephalosporines (due to extended-spectrum (ESBL) or AmpC beta-lactamases) or to carbapenems (for example carbapenem producing Enterobacteriales (CPE)), the treatment options become limited....

Cite
Yusuf E, Bax HI, Verkaik NJ, et al. An Update on Eight "New" Antibiotics against Multidrug-Resistant Gram-Negative Bacteria. J Clin Med. 2021;10(5)doi: 10.3390/jcm10051068.
Yusuf, E., Bax, H. I., Verkaik, N. J., & van Westreenen, M. (2021). An Update on Eight "New" Antibiotics against Multidrug-Resistant Gram-Negative Bacteria. Journal of clinical medicine, 10(5), . https://doi.org/10.3390/jcm10051068
Yusuf, Erlangga, et al. "An Update on Eight "New" Antibiotics against Multidrug-Resistant Gram-Negative Bacteria." Journal of clinical medicine vol. 10,5 (2021). doi: https://doi.org/10.3390/jcm10051068
Yusuf E, Bax HI, Verkaik NJ, van Westreenen M. An Update on Eight "New" Antibiotics against Multidrug-Resistant Gram-Negative Bacteria. J Clin Med. 2021 Mar 04;10(5). doi: 10.3390/jcm10051068. PMID: 33806604; PMCID: PMC7962006.
Copy Download .nbib Format: NLM
CON: Carbapenems are NOT necessary for all infections caused by ceftriaxone-resistant Enterobacterales.

JAC-antimicrobial resistance

Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Pascual A.
PMID: 34223064
JAC Antimicrob Resist. 2021 Feb 24;3(1):dlaa112. doi: 10.1093/jacamr/dlaa112. eCollection 2021 Mar.

Carbapenems are considered the drugs of choice for the treatment of serious infections caused by ceftriaxone-resistant Enterobacterales. However, because of the dramatic increase in carbapenem-resistant organisms worldwide, finding alternatives to carbapenems is a must. The potential options include β-lactam/β-lactamase...

Cite
Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Pascual A. CON: Carbapenems are NOT necessary for all infections caused by ceftriaxone-resistant Enterobacterales. JAC Antimicrob Resist. 2021;3(1):dlaa112doi: 10.1093/jacamr/dlaa112.
Rodríguez-Baño, J., Gutiérrez-Gutiérrez, B., & Pascual, A. (2021). CON: Carbapenems are NOT necessary for all infections caused by ceftriaxone-resistant Enterobacterales. JAC-antimicrobial resistance, 3(1), dlaa112. https://doi.org/10.1093/jacamr/dlaa112
Rodríguez-Baño, Jesús, et al. "CON: Carbapenems are NOT necessary for all infections caused by ceftriaxone-resistant Enterobacterales." JAC-antimicrobial resistance vol. 3,1 (2021): dlaa112. doi: https://doi.org/10.1093/jacamr/dlaa112
Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Pascual A. CON: Carbapenems are NOT necessary for all infections caused by ceftriaxone-resistant Enterobacterales. JAC Antimicrob Resist. 2021 Feb 24;3(1):dlaa112. doi: 10.1093/jacamr/dlaa112. eCollection 2021 Mar. PMID: 34223064; PMCID: PMC8210108.
Copy Download .nbib Format: NLM
Activity of temocillin against third-generation cephalosporin-resistant .

JAC-antimicrobial resistance

Stewart AG, Henderson A, Bauer MJ, Paterson DL, Harris PNA.
PMID: 34988445
JAC Antimicrob Resist. 2021 Dec 28;4(1):dlab192. doi: 10.1093/jacamr/dlab192. eCollection 2022 Mar.

BACKGROUND: Extended spectrum β-lactamase (ESBL) and AmpC-producing Gram-negative bacilli contribute significantly to the antimicrobial resistance (AMR) burden worldwide. Temocillin is an intravenous semisynthetic antibiotic that is stable to hydrolysis by ESBLs and AmpC. Temocillin may be a treatment option...

Cite
Stewart AG, Henderson A, Bauer MJ, et al. Activity of temocillin against third-generation cephalosporin-resistant . JAC Antimicrob Resist. 2021;4(1):dlab192doi: 10.1093/jacamr/dlab192.
Stewart, A. G., Henderson, A., Bauer, M. J., Paterson, D. L., & Harris, P. N. A. (2022). Activity of temocillin against third-generation cephalosporin-resistant . JAC-antimicrobial resistance, 4(1), dlab192. https://doi.org/10.1093/jacamr/dlab192
Stewart, Adam G, et al. "Activity of temocillin against third-generation cephalosporin-resistant ." JAC-antimicrobial resistance vol. 4,1 (2022): dlab192. doi: https://doi.org/10.1093/jacamr/dlab192
Stewart AG, Henderson A, Bauer MJ, Paterson DL, Harris PNA. Activity of temocillin against third-generation cephalosporin-resistant . JAC Antimicrob Resist. 2021 Dec 28;4(1):dlab192. doi: 10.1093/jacamr/dlab192. eCollection 2022 Mar. PMID: 34988445; PMCID: PMC8712245.
Copy Download .nbib Format: NLM
Clinical outcomes of temocillin use for invasive Enterobacterales infections: a single-centre retrospective analysis.

JAC-antimicrobial resistance

Heard KL, Killington K, Mughal N, Moore LSP, Hughes S.
PMID: 34223083
JAC Antimicrob Resist. 2021 Feb 14;3(1):dlab005. doi: 10.1093/jacamr/dlab005. eCollection 2021 Mar.

BACKGROUND: With increasing frequency of resistant Gram-negative bacteria, temocillin has potential utility in reducing carbapenem use. The 2020 EUCAST guideline changes temocillin breakpoints and reclassifies isolates with an MIC of 0.001-16 mg/L as 'susceptible, increased exposure' necessitating 6 g/day...

Cite
Heard KL, Killington K, Mughal N, et al. Clinical outcomes of temocillin use for invasive Enterobacterales infections: a single-centre retrospective analysis. JAC Antimicrob Resist. 2021;3(1):dlab005doi: 10.1093/jacamr/dlab005.
Heard, K. L., Killington, K., Mughal, N., Moore, L. S. P., & Hughes, S. (2021). Clinical outcomes of temocillin use for invasive Enterobacterales infections: a single-centre retrospective analysis. JAC-antimicrobial resistance, 3(1), dlab005. https://doi.org/10.1093/jacamr/dlab005
Heard, Katie L, et al. "Clinical outcomes of temocillin use for invasive Enterobacterales infections: a single-centre retrospective analysis." JAC-antimicrobial resistance vol. 3,1 (2021): dlab005. doi: https://doi.org/10.1093/jacamr/dlab005
Heard KL, Killington K, Mughal N, Moore LSP, Hughes S. Clinical outcomes of temocillin use for invasive Enterobacterales infections: a single-centre retrospective analysis. JAC Antimicrob Resist. 2021 Feb 14;3(1):dlab005. doi: 10.1093/jacamr/dlab005. eCollection 2021 Mar. PMID: 34223083; PMCID: PMC8210019.
Copy Download .nbib Format: NLM
The penicillins.

Mayo Clinic proceedings

Wright AJ, Wilkowske CJ.
PMID: 1921489
Mayo Clin Proc. 1991 Oct;66(10):1047-63. doi: 10.1016/s0025-6196(12)61730-3.

The penicillin family of antibiotics remains an important part of our antimicrobial armamentarium. In general, these agents have bactericidal activity, excellent distribution throughout the body, low toxicity, and efficacy against infections caused by susceptible bacteria. The initial introduction of...

Cite
Wright AJ, Wilkowske CJ. The penicillins. Mayo Clin Proc. 1991;66(10):1047-63doi: 10.1016/s0025-6196(12)61730-3.
Wright, A. J., & Wilkowske, C. J. (1991). The penicillins. Mayo Clinic proceedings, 66(10), 1047-63. https://doi.org/10.1016/s0025-6196(12)61730-3
Wright, A J, and Wilkowske, C J. "The penicillins." Mayo Clinic proceedings vol. 66,10 (1991): 1047-63. doi: https://doi.org/10.1016/s0025-6196(12)61730-3
Wright AJ, Wilkowske CJ. The penicillins. Mayo Clin Proc. 1991 Oct;66(10):1047-63. doi: 10.1016/s0025-6196(12)61730-3. PMID: 1921489.
Copy Download .nbib Format: NLM
Evaluation of Combined Use of Temocillin Disk and Mastdisks Inhibitor Combination Set Against Polymerase Chain Reaction for Detection of Carbapenem-Resistant .

Open access Macedonian journal of medical sciences

Shaker OA, Gomaa HE, ElMasry SA, Halim RMA, Abdelrahman AH, Kamal JS.
PMID: 29531581
Open Access Maced J Med Sci. 2018 Feb 01;6(2):242-247. doi: 10.3889/oamjms.2018.090. eCollection 2018 Feb 15.

AIM: To evaluate the diagnostic performance of MDI and temocillin disk (30 μg) for detection of carbapenem-resistant MATERIAL AND METHODS: Fifty specimens submitted to the Microbiology Laboratory of Ain Shams University Hospitals and showed resistance to carbapenem drugs through...

Cite
Shaker OA, Gomaa HE, ElMasry SA, et al. Evaluation of Combined Use of Temocillin Disk and Mastdisks Inhibitor Combination Set Against Polymerase Chain Reaction for Detection of Carbapenem-Resistant . Open Access Maced J Med Sci. 2018;6(2):242-247doi: 10.3889/oamjms.2018.090.
Shaker, O. A., Gomaa, H. E., ElMasry, S. A., Halim, R. M. A., Abdelrahman, A. H., & Kamal, J. S. (2018). Evaluation of Combined Use of Temocillin Disk and Mastdisks Inhibitor Combination Set Against Polymerase Chain Reaction for Detection of Carbapenem-Resistant . Open access Macedonian journal of medical sciences, 6(2), 242-247. https://doi.org/10.3889/oamjms.2018.090
Shaker, Omnia A, et al. "Evaluation of Combined Use of Temocillin Disk and Mastdisks Inhibitor Combination Set Against Polymerase Chain Reaction for Detection of Carbapenem-Resistant ." Open access Macedonian journal of medical sciences vol. 6,2 (2018): 242-247. doi: https://doi.org/10.3889/oamjms.2018.090
Shaker OA, Gomaa HE, ElMasry SA, Halim RMA, Abdelrahman AH, Kamal JS. Evaluation of Combined Use of Temocillin Disk and Mastdisks Inhibitor Combination Set Against Polymerase Chain Reaction for Detection of Carbapenem-Resistant . Open Access Maced J Med Sci. 2018 Feb 01;6(2):242-247. doi: 10.3889/oamjms.2018.090. eCollection 2018 Feb 15. PMID: 29531581; PMCID: PMC5839425.
Copy Download .nbib Format: NLM
Insights into Newer Antimicrobial Agents Against Gram-negative Bacteria.

Microbiology insights

Taneja N, Kaur H.
PMID: 27013887
Microbiol Insights. 2016 Mar 20;9:9-19. doi: 10.4137/MBI.S29459. eCollection 2016.

Currently, drug resistance, especially against cephalosporins and carbapenems, among gram-negative bacteria is an important challenge, which is further enhanced by the limited availability of drugs against these bugs. There are certain antibiotics (colistin, fosfomycin, temocillin, and rifampicin) that have...

Cite
Taneja N, Kaur H. Insights into Newer Antimicrobial Agents Against Gram-negative Bacteria. Microbiol Insights. 2016;9:9-19doi: 10.4137/MBI.S29459.
Taneja, N., & Kaur, H. (2016). Insights into Newer Antimicrobial Agents Against Gram-negative Bacteria. Microbiology insights, 99-19. https://doi.org/10.4137/MBI.S29459
Taneja, Neelam, and Kaur, Harsimran. "Insights into Newer Antimicrobial Agents Against Gram-negative Bacteria." Microbiology insights vol. 9 (2016): 9-19. doi: https://doi.org/10.4137/MBI.S29459
Taneja N, Kaur H. Insights into Newer Antimicrobial Agents Against Gram-negative Bacteria. Microbiol Insights. 2016 Mar 20;9:9-19. doi: 10.4137/MBI.S29459. eCollection 2016. PMID: 27013887; PMCID: PMC4803319.
Copy Download .nbib Format: NLM
Carbapenem-Sparing Strategies for ESBL Producers: When and How.

Antibiotics (Basel, Switzerland)

Karaiskos I, Giamarellou H.
PMID: 32033322
Antibiotics (Basel). 2020 Feb 05;9(2). doi: 10.3390/antibiotics9020061.

Extended spectrum β-lactamase (ESBL)-producing bacteria are prevalent worldwide and correlated with hospital infections, but they have been evolving as an increasing cause of community acquired infections. The spread of ESBL constitutes a major threat for public health, and infections...

Cite
Karaiskos I, Giamarellou H. Carbapenem-Sparing Strategies for ESBL Producers: When and How. Antibiotics (Basel). 2020;9(2)doi: 10.3390/antibiotics9020061.
Karaiskos, I., & Giamarellou, H. (2020). Carbapenem-Sparing Strategies for ESBL Producers: When and How. Antibiotics (Basel, Switzerland), 9(2), . https://doi.org/10.3390/antibiotics9020061
Karaiskos, Ilias, and Giamarellou, Helen. "Carbapenem-Sparing Strategies for ESBL Producers: When and How." Antibiotics (Basel, Switzerland) vol. 9,2 (2020). doi: https://doi.org/10.3390/antibiotics9020061
Karaiskos I, Giamarellou H. Carbapenem-Sparing Strategies for ESBL Producers: When and How. Antibiotics (Basel). 2020 Feb 05;9(2). doi: 10.3390/antibiotics9020061. PMID: 32033322; PMCID: PMC7167803.
Copy Download .nbib Format: NLM
Successful Use of Temocillin as Salvage Therapy for Cervical Osteomyelitis Secondary to Multidrug-Resistant Burkholderia cepacia.

Journal of the Pediatric Infectious Diseases Society

Rodriguez M, Nelson M, Kelly JE, Elward A, Morley SC.
PMID: 26624908
J Pediatric Infect Dis Soc. 2014 Mar;3(1):77-80. doi: 10.1093/jpids/pis110. Epub 2013 Jan 08.

Infection with multidrug resistant Burkholderia cepacia presents a therapeutic challenge in patients with cystic fibrosis. In this study, we present a case of progressive cervical osteomyelitis secondary to B cepacia that failed surgical drainage and extended therapy with meropenem,...

Cite
Rodriguez M, Nelson M, Kelly JE, et al. Successful Use of Temocillin as Salvage Therapy for Cervical Osteomyelitis Secondary to Multidrug-Resistant Burkholderia cepacia. J Pediatric Infect Dis Soc. 2013;3(1):77-80doi: 10.1093/jpids/pis110.
Rodriguez, M., Nelson, M., Kelly, J. E., Elward, A., & Morley, S. C. (2014). Successful Use of Temocillin as Salvage Therapy for Cervical Osteomyelitis Secondary to Multidrug-Resistant Burkholderia cepacia. Journal of the Pediatric Infectious Diseases Society, 3(1), 77-80. https://doi.org/10.1093/jpids/pis110
Rodriguez, Marcela, et al. "Successful Use of Temocillin as Salvage Therapy for Cervical Osteomyelitis Secondary to Multidrug-Resistant Burkholderia cepacia." Journal of the Pediatric Infectious Diseases Society vol. 3,1 (2014): 77-80. doi: https://doi.org/10.1093/jpids/pis110
Rodriguez M, Nelson M, Kelly JE, Elward A, Morley SC. Successful Use of Temocillin as Salvage Therapy for Cervical Osteomyelitis Secondary to Multidrug-Resistant Burkholderia cepacia. J Pediatric Infect Dis Soc. 2014 Mar;3(1):77-80. doi: 10.1093/jpids/pis110. Epub 2013 Jan 08. PMID: 26624908.
Copy Download .nbib Format: NLM
Intravenous colistin in the treatment of multidrug-resistant gram-negative organism in tertiary hospital, Jazan, KSA.

Journal of family medicine and primary care

Ali EM, Albarraq AA, Makeen HA, Ezzi A, Mashragi YAM.
PMID: 34017749
J Family Med Prim Care. 2021 Jan;10(1):333-338. doi: 10.4103/jfmpc.jfmpc_1148_20. Epub 2021 Jan 30.

BACKGROUND: It was considered that the resistance of drugs such as carbapenems and cephalosporins against severe or high risk gram-negative bacteria became a tremendous confront. This might be attributed to the little amount of these drugs to be used...

Cite
Ali EM, Albarraq AA, Makeen HA, et al. Intravenous colistin in the treatment of multidrug-resistant gram-negative organism in tertiary hospital, Jazan, KSA. J Family Med Prim Care. 2021;10(1):333-338doi: 10.4103/jfmpc.jfmpc_1148_20.
Ali, E. M., Albarraq, A. A., Makeen, H. A., Ezzi, A., & Mashragi, Y. A. M. (2021). Intravenous colistin in the treatment of multidrug-resistant gram-negative organism in tertiary hospital, Jazan, KSA. Journal of family medicine and primary care, 10(1), 333-338. https://doi.org/10.4103/jfmpc.jfmpc_1148_20
Ali, Eman M, et al. "Intravenous colistin in the treatment of multidrug-resistant gram-negative organism in tertiary hospital, Jazan, KSA." Journal of family medicine and primary care vol. 10,1 (2021): 333-338. doi: https://doi.org/10.4103/jfmpc.jfmpc_1148_20
Ali EM, Albarraq AA, Makeen HA, Ezzi A, Mashragi YAM. Intravenous colistin in the treatment of multidrug-resistant gram-negative organism in tertiary hospital, Jazan, KSA. J Family Med Prim Care. 2021 Jan;10(1):333-338. doi: 10.4103/jfmpc.jfmpc_1148_20. Epub 2021 Jan 30. PMID: 34017749; PMCID: PMC8132804.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 14 entries